Skip to content
TrialScanner

NCT03599453

Chemokine Modulation Therapy and Pembrolizumab in Treating Participants With Metastatic Triple-Negative Breast Cancer

Early Phase 1CompletedAIMCollaborator

Registry record

Lead sponsor
Roswell Park Cancer Institute
Conditions
Triple -Negative Breast Cancer; Estrogen Receptor Negative; HER2/Neu Negative; Anatomic Stage IV Breast Cancer AJCC; Progesterone Receptor Negative
Primary completion
Sep 2, 2020Actual
Completion
Locked
Start
Locked
Enrollment
Locked
Interventions
Locked
Study type
Locked
Results on the registry
Locked
Record last updated
Locked

Open NCT03599453 on ClinicalTrials.gov

Enrollment, interventions, the start and completion dates and the change history are locked on 1 row here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.

Unlock with TrialScanner

Recorded changes

0 changes recorded for this trial. The history, with each previous value, is part of TrialScanner.

Tracking since Nov 12, 2026. Changes before that date are not known to TrialScanner.

    NCT03599453: Chemokine Modulation Therapy... | TrialScanner